AN
ANTH.US Anthera Pharmaceuticals Inc
- Market cap
- USD 2.62K
- P/E
- -
- P/B
- 0.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is ANTH.US undervalued?
Graham numberThe Graham number of Anthera Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anthera Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Anthera Pharmaceuticals Inc yet.
Anthera Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including im…
Full company profileAnthera Pharmaceuticals Inc financial statements
Anthera Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 3.19M | 145K | 0.00 | - | - | - | - |
| Gross Profit | -24.2K | -21.7K | -21.8M | 3.15M | 98.7K | -281K | - | - | - | - |
| Operating Income | -55.9M | -28.2M | -28.5M | -35.2M | -57.2M | -36.4M | - | - | - | - |
| EBITDA | -55.6M | -27.9M | -28.1M | -35.0M | -56.9M | -26.6M | - | - | - | - |
| Net Income | -59.4M | -33.1M | -30.3M | -34.9M | -53.6M | -16.9M | - | - | - | - |
| EPS | -66 | -14 | -11 | -7.84 | -10 | -1.65 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 26.4M | 37.4M | 3.49M | 48.1M | 23.5M | 3.67M | - | - | - | - |
| Total Liabilities | 30.0M | 22.7M | 5.75M | 8.47M | 11.0M | 9.17M | - | - | - | - |
| Shareholders' Equity | -3.53M | 14.8M | -2.26M | 39.7M | 12.5M | -5.50M | - | - | - | - |
| Cash & Short-term Investments | 24.8M | 25.9M | 2.64M | 47.0M | 20.8M | 2.20M | - | - | - | - |
| Total Debt | 20.6M | 17.9M | - | - | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -73.6M | -31.9M | -25.6M | -30.9M | -48.9M | -36.9M | - | - | - | - |
| Capital Expenditure | 207K | 15.0K | 80.0K | 80.0K | 766K | 920K | - | - | - | - |
| Free Cash Flow | -73.8M | -31.9M | -25.6M | -31.0M | -49.7M | -36.9M | - | - | - | - |
| Ratios | ||||||||||
| ROE | - | -224.3% | - | -88.0% | -429.9% | - | - | - | - | - |
| ROA | -224.6% | -88.5% | -868.5% | -72.5% | -228.4% | -461.1% | - | - | - | - |
| Net Profit Margin | - | - | - | -1,096.1% | -36,967.6% | - | - | - | - | - |
| Debt to Equity | - | 1.21x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anthera Pharmaceuticals Inc dividends
Anthera Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on May 1, 2017.
Who owns Anthera Pharmaceuticals Inc
Ownership data of Anthera Pharmaceuticals Inc is not available yet.
Anthera Pharmaceuticals Inc company profile
- Company name
- Anthera Pharmaceuticals Inc
- Ticker
- ANTH.US
- Exchange
- USA Stocks
- Listed since
- Mar 1, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- The Pennzoil Building, Houston, TX, United States, 77002
- Phone
- 410 350 1839
- Website
- anthera.com
About Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Anthera Pharmaceuticals Inc management
4- Mr. Paul F. Truex M.B.A.Executive Chairman · born 1969
- Ms. May Liu CPASenior VP of Finance & Administration and Principal Accounting Officer · born 1976
- Dr. Paul Adams Ph.D.Senior Vice President of Global Regulatory Affairs and Compliance · born 1963
- Joshua CaldwellChief Liquidating Officer